TVRD
NASDAQTvardi Therapeutics Inc.
$3.11+0.16 (+5.42%)
News25/Ratings11
Price$3.11+0.01 (+0.32%)
03:00 PM07:30 PM
News · 26 weeks31+350%
2025-10-262026-04-19
Mix1690d
- SEC Filings9(56%)
- Insider4(25%)
- Other2(13%)
- Analyst1(6%)
Latest news
25 items- SECSEC Form DEFA14A filed by Tvardi Therapeutics Inc.DEFA14A - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- SECSEC Form DEF 14A filed by Tvardi Therapeutics Inc.DEF 14A - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- ANALYSTTvardi Therapeutics downgraded by Barclays with a new price targetBarclays downgraded Tvardi Therapeutics from Equal Weight to Underweight and set a new price target of $3.00
- SECSEC Form S-8 filed by Tvardi Therapeutics Inc.S-8 - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- SECSEC Form POS EX filed by Tvardi Therapeutics Inc.POS EX - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- SECSEC Form 424B3 filed by Tvardi Therapeutics Inc.424B3 - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- SECSEC Form 10-K filed by Tvardi Therapeutics Inc.10-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- SECTvardi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- PRTvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business UpdateResults from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 2026 Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) are anticipated in H2 2026 Cash runway expected to be sufficient to fund operations into Q4 2026 after clinical readouts HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced its financial and operating results for the fourth quarter and full-year ended December 31, 2025, and prov
- SECSEC Form 424B3 filed by Tvardi Therapeutics Inc.424B3 - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- SECTvardi Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- PRTvardi Therapeutics to Participate in Upcoming Investor ConferencesHOUSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that management will participate in the following upcoming investor conferences: JonesTrading C-Suite Fireside Chat SeriesDate: Wednesday, February 19, 2026Time: 11:00 AM ESTRegistration Link here Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFormat: Corporate presentationDate: Wednesday, February 25, 2026Time: 10:40 AM ESTLocation: Virtual TD Cowen 46th Annual Health Care ConferenceFormat: Corporate prese
- INSIDERSEC Form 4 filed by Chief Financial Officer Conn Avi Daniel4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
- INSIDERSEC Form 4 filed by Principal Accounting Officer O'Brien Stephen Paul4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Kauh John Saewook M.D.4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Alibhai Imran Nizamudin4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
- SECTvardi Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- PRTvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceHOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that management will deliver a company presentation during the 44th Annual J.P. Morgan Healthcare Conference, being held January 12th – 15th, 2026, in San Francisco, CA. During the presentation, Tvardi will discuss and provide additional context around the new Phase 2 REVERT IPF clinical trial data for TTI-101 reported today. These new data demonstrate encouraging signals across fibrosis, inflammatory markers and pulmona
- PRTvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical InsightsPooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the placebo group Topline healthy volunteer data from Phase 1 study of next-generation STAT3 inhibitor, TTI-109, on track for H1 2026 HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today provided further updates from its Phase 2 REVERT IPF clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF). Preliminary results were announced on
- SECTvardi Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Alibhai Imran Nizamudin4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Conn Avi Daniel4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Kauh John Saewook M.D.4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
- INSIDERSEC Form 4 filed by Principal Accounting Officer O'Brien Stephen Paul4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
- SECTvardi Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)